Eli Lilly launched TuneLab, a new AI platform offering drug discovery models trained on decades of Lilly research for use by selected biotechs at no cost. The initiative aims to leverage federated learning to ensure data privacy, with Lilly expecting partners to contribute training data to improve model performance. This democratization of AI resources supports innovation and efficiency in small biopharma, aligning with Lilly’s broader Catalyze360 program to foster external collaborations using disruptive technologies.